{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T20:17:28Z","timestamp":1726085848677},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,11,7]],"date-time":"2007-11-07T00:00:00Z","timestamp":1194393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s11926-007-0072-4","type":"journal-article","created":{"date-parts":[[2007,11,6]],"date-time":"2007-11-06T06:26:18Z","timestamp":1194330378000},"page":"442-448","source":"Crossref","is-referenced-by-count":8,"title":["Psoriatic arthritis: Current topics"],"prefix":"10.1007","volume":"9","author":[{"given":"David","family":"McCarey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,11,7]]},"reference":[{"key":"72_CR1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"J.M. Moll","year":"1973","unstructured":"Moll JM, Wright V: Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55\u201378.","journal-title":"Semin Arthritis Rheum"},{"key":"72_CR2","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W. Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, et al.: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665\u20132673.","journal-title":"Arthritis Rheum"},{"key":"72_CR3","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1161\/01.CIR.0000099844.31524.05","volume":"108","author":"N. Sattar","year":"2003","unstructured":"Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how \u201chigh-grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957\u20132963.","journal-title":"Circulation"},{"key":"72_CR4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.semarthrit.2004.07.010","volume":"34","author":"M.J. Peters","year":"2004","unstructured":"Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT: Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004, 34:585\u2013592.","journal-title":"Semin Arthritis Rheum"},{"key":"72_CR5","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1002\/art.22800","volume":"56","author":"Y. Ali","year":"2007","unstructured":"Ali Y, Tom BD, Schentag CT, et al.: Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum 2007, 56:2708\u20132714.","journal-title":"Arthritis Rheum"},{"key":"72_CR6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","volume":"41","author":"D.D. Gladman","year":"1998","unstructured":"Gladman DD, Farewell VT, Wong K, Husted J: Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death, Arthritis Rheum 1998, 41:1103\u20131110.","journal-title":"Arthritis Rheum"},{"key":"72_CR7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/art.22530","volume":"57","author":"C. Gonzalez-Juanatey","year":"2007","unstructured":"Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, et al.: Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:287\u2013293.","journal-title":"Arthritis Rheum"},{"key":"72_CR8","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.22884","volume":"57","author":"C. Gonzalez-Juanatey","year":"2007","unstructured":"Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, et al.: High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:1074\u20131080.","journal-title":"Arthritis Rheum"},{"key":"72_CR9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/art.22447","volume":"56","author":"N. Sattar","year":"2007","unstructured":"Sattar N, Crompton P, Cherry L, et al.: Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007, 56:831\u2013839.","journal-title":"Arthritis Rheum"},{"key":"72_CR10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.1964.03070100037007","volume":"189","author":"R.L. Black","year":"1964","unstructured":"Black RL, O\u2019Brien WM, Vanscott EJ, et al.: Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 1964, 189:743\u2013747.","journal-title":"JAMA"},{"key":"72_CR11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","volume":"27","author":"R.F. Willkens","year":"1984","unstructured":"Willkens RF, Williams HJ, Ward JR, et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984, 27:376\u2013381.","journal-title":"Arthritis Rheum"},{"key":"72_CR12","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1002\/art.20518","volume":"50","author":"D. Kane","year":"2004","unstructured":"Kane D, Gogarty M, O\u2019leary J, et al.: Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004, 50:3286\u20133295.","journal-title":"Arthritis Rheum"},{"key":"72_CR13","first-page":"589","volume":"13","author":"A. Spadaro","year":"1995","unstructured":"Spadaro A, Riccieri V, Sili-Scavalli A, et al.: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995, 13:589\u2013593.","journal-title":"Clin Exp Rheumatol"},{"key":"72_CR14","first-page":"609","volume":"15","author":"A. Spadaro","year":"1997","unstructured":"Spadaro A, Taccari E, Mohtadi B, et al.: Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs. Clin Exp Rheumatol 1997, 15:609\u2013614.","journal-title":"Clin Exp Rheumatol"},{"key":"72_CR15","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","volume":"42","author":"D.O. Clegg","year":"1999","unstructured":"Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999, 42:2325\u20132329.","journal-title":"Arthritis Rheum"},{"key":"72_CR16","first-page":"1724","volume":"19","author":"D.D. Gladman","year":"1992","unstructured":"Gladman DD, Blake R, Brubacher B, Farewell VT: Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992, 19:1724\u20131726.","journal-title":"J Rheumatol"},{"key":"72_CR17","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"J.P. Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D, et al: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004, 50:1939\u20131950.","journal-title":"Arthritis Rheum"},{"key":"72_CR18","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"C.E. Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227\u20131236. [Erratum in: Arthritis Rheum 2005, 52:2951.]","journal-title":"Arthritis Rheum"},{"key":"72_CR19","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","volume":"66","author":"A. Kavanaugh","year":"2007","unstructured":"Kavanaugh A, Krueger GG, Beutler A, et al.: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66:498\u2013505.","journal-title":"Ann Rheum Dis"},{"key":"72_CR20","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","volume":"56","author":"D. Heijde van der","year":"2007","unstructured":"van der Heijde D, Kavanaugh A, Gladman DD, et al.: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56:2698\u20132707.","journal-title":"Arthritis Rheum"},{"key":"72_CR21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"D.D. Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Ritchlin CT, et al.: Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007, 56:476\u2013488.","journal-title":"Arthritis Rheum"},{"key":"72_CR22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2006.057901","volume":"66","author":"D.D. Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Cifaldi MA, et al.: Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007, 66:163\u2013168.","journal-title":"Ann Rheum Dis"},{"key":"72_CR23","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"P.J. Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264\u20132272.","journal-title":"Arthritis Rheum"},{"key":"72_CR24","first-page":"712","volume":"33","author":"P.J. Mease","year":"2006","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712\u2013721.","journal-title":"J Rheumatol"},{"key":"72_CR25","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","volume":"54","author":"P.J. Mease","year":"2006","unstructured":"Mease PJ, Gladman DD, Keystone EC, Alefacept in Psoriatic Arthritis Study Group: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006, 54:1638\u20131645.","journal-title":"Arthritis Rheum"},{"key":"72_CR26","doi-asserted-by":"crossref","first-page":"9558","DOI":"10.1074\/jbc.270.16.9558","volume":"270","author":"P. Wang","year":"1995","unstructured":"Wang P, Wu P, Siegel MI, et al.: Interleukin (IL)-10 inhibits nuclear factor k B (NF k B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995, 270:9558\u20139563.","journal-title":"J Biol Chem"},{"key":"72_CR27","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1002\/eji.1830250940","volume":"25","author":"C. Buelens","year":"1995","unstructured":"Buelens C, Willems F, Delvaux A, et al.: Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995, 25:2668\u20132672.","journal-title":"Eur J Immunol"},{"key":"72_CR28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/eji.1830250213","volume":"25","author":"C.H. Chang","year":"1995","unstructured":"Chang CH, Furue M, Tamaki K: B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-g or by interleukin-10. Eur J Immunol 1995, 25:394\u2013398.","journal-title":"Eur J Immunol"},{"key":"72_CR29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/39614","volume":"389","author":"H. Groux","year":"1997","unstructured":"Groux H, O\u2019Garra A, Bigler M, et al.: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737\u2013742.","journal-title":"Nature"},{"key":"72_CR30","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1172\/JCI1476","volume":"101","author":"K. Asadullah","year":"1998","unstructured":"Asadullah K, Sterry W, Stephanek K, et al.: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998, 101:783\u2013794.","journal-title":"J Clin Invest"},{"key":"72_CR31","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1074\/jbc.M208602200","volume":"278","author":"C. Chang","year":"2003","unstructured":"Chang C, Magracheva E, Kozlov S, et al.: Crystal structure of interleukin-19 defines a new subfamily of helical cytokines. J Biol Chem 2003, 278:3308\u20133313.","journal-title":"J Biol Chem"},{"key":"72_CR32","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/j.1523-1747.2003.12626.x","volume":"121","author":"J. Romer","year":"2003","unstructured":"Romer J, Hasselager E, Norby PL, et al.: Epidermal overexpression of interleukin-19 and-20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol 2003, 121:1306\u20131311.","journal-title":"J Invest Dermatol"},{"key":"72_CR33","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.4049\/jimmunol.178.4.2229","volume":"178","author":"S.M. Sa","year":"2007","unstructured":"Sa SM, Valdez PA, Wu J, et al.: The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007, 178:2229\u20132240.","journal-title":"J Immunol"},{"key":"72_CR34","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","volume":"203","author":"J.R. Chan","year":"2006","unstructured":"Chan JR, Blumenschein W, Murphy E, et al.: IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006, 203:2577\u20132587.","journal-title":"J Exp Med"},{"key":"72_CR35","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.4049\/jimmunol.169.8.4288","volume":"169","author":"Y.C. Liao","year":"2002","unstructured":"Liao YC, Liang WG, Chen FW, et al.: IL-19 induces production of IL-6 and TNF-a and results in cell apoptosis through TNF-a. J Immunol 2002, 169:4288\u20134297.","journal-title":"J Immunol"},{"key":"72_CR36","doi-asserted-by":"crossref","first-page":"47517","DOI":"10.1074\/jbc.M205114200","volume":"277","author":"J. Parrish-Novak","year":"2002","unstructured":"Parrish-Novak J, Xu W, Brender T, et al.: Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002, 277:47517\u201347523.","journal-title":"J Biol Chem"},{"key":"72_CR37","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","volume":"445","author":"Y. Zheng","year":"2007","unstructured":"Zheng Y, Danilenko DM, Valdez P, et al.: Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648\u2013651.","journal-title":"Nature"},{"key":"72_CR38","doi-asserted-by":"crossref","first-page":"33343","DOI":"10.1074\/jbc.M405000200","volume":"279","author":"S. Hor","year":"2004","unstructured":"Hor S, Pirzer H, Dumoutier L, et al.: The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem 2004, 279:33343\u201333351.","journal-title":"J Biol Chem"},{"key":"72_CR39","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.172.3.1935","volume":"172","author":"S.A. Curran","year":"2004","unstructured":"Curran SA, FitzGerald OM, Costello PJ, et al.: Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 2004, 172:1935\u20131944.","journal-title":"J Immunol"},{"key":"72_CR40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0198-8859(99)00034-8","volume":"60","author":"I. Tassiulas","year":"1999","unstructured":"Tassiulas I, Duncan SR, Centola M, et al.: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 1999, 60:479\u2013491.","journal-title":"Hum Immunol"},{"key":"72_CR41","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1523-1747.1998.00446.x","volume":"111","author":"N. Yawalkar","year":"1998","unstructured":"Yawalkar N, Karlen S, Hunger R, et al.: Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998, 111:1053\u20131057.","journal-title":"J Invest Dermatol"},{"key":"72_CR42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","volume":"356","author":"G.G. Krueger","year":"2007","unstructured":"Krueger GG, Langley RG, Leonardi C, et al.: A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356:580\u2013592.","journal-title":"N Engl J Med"},{"key":"72_CR43","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","volume":"203","author":"J.R. Chan","year":"2006","unstructured":"Chan JR, Blumenschein W, Murphy E, et al.: IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006, 203:2577\u20132587.","journal-title":"J Exp Med"},{"key":"72_CR44","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1002\/art.22590","volume":"56","author":"K. Reich","year":"2007","unstructured":"Reich K, Hassffmeier U, Kassnig IR, et al.: TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 2007, 56:2056\u20132064.","journal-title":"Arthritis Rheum"},{"key":"72_CR45","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/ard.2005.039164","volume":"65","author":"P. Rahman","year":"2006","unstructured":"Rahman P, Siannis F, Butt C, et al.: TNFalpha polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006, 65:919\u2013923.","journal-title":"Ann Rheum Dis"},{"key":"72_CR46","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/art.21928","volume":"54","author":"P. Rahman","year":"2006","unstructured":"Rahman P, Sun S, Peddle L, et al.: Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006, 54:2321\u20132325.","journal-title":"Arthritis Rheum"},{"key":"72_CR47","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/ard.2006.064972","volume":"66","author":"P.Y. Ho","year":"2007","unstructured":"Ho PY, Barton A, Worthington J, et al.: HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis 2007, 66:807\u2013811.","journal-title":"Ann Rheum Dis"},{"key":"72_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2474-8-1","volume":"8","author":"C. Butt","year":"2007","unstructured":"Butt C, Lim S, Greenwood C, Rahman P: VEGF, FGF1, FGF2 and EGF gene polymorphisms and psoriatic arthritis. BMC Musculoskelet Disord 2007, 8:1.","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-007-0072-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-007-0072-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-007-0072-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:49:48Z","timestamp":1559436588000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-007-0072-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,7]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1007\/s11926-007-0072-4","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,7]]}}}